- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03474679
A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
30. desember 2021 oppdatert av: Janssen Pharmaceutical K.K.
A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and partial response [PR] defined by National Institutes of Health [NIH] consensus development project criteria [2014]).
Studieoversikt
Studietype
Intervensjonell
Registrering (Faktiske)
19
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Anjo-shi, Japan, 446-8602
- Anjo Kosei Hospital
-
Bunkyo-ku, Japan, 113-8677
- Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
-
Hiroshima, Japan, 730-8619
- Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
-
Hyogo, Japan, 650-0047
- Kobe City Medical Center General Hospital
-
Isehara, Japan, 259-1193
- Tokai University Hospital
-
Izumi, Japan, 594-1101
- Osaka Women's and Children's Hospital
-
Kumamoto, Japan, 860-0008
- National Hospital Organization Kumamoto Medical Center
-
Kurashiki, Japan, 710-8602
- Kurashiki Central Hospital
-
Maebashi, Japan, 371-0821
- Gunmaken Saiseikai Maebashi Hospital
-
Nagoya, Japan, 453-8511
- Japanese Red Cross Nagoya Daiichi Hospital
-
Nishinomiya, Japan, 663-8501
- The Hospital of Hyogo College of Medicine
-
Okayama, Japan, 700-8558
- Okayama University Hospital
-
Osaka, Japan, 545-8586
- Osaka City University Hospital
-
Sapporo-shi, Japan, 060-8648
- Hokkaido University Hospital
-
Setagaya-ku, Japan, 157-8535
- National Center for Child Health and Development
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
12 år og eldre (Barn, Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Steroid dependent/refractory chronic graft versus host disease (cGVHD) defined as modified National Institutes of Health (NIH) criteria (2014) below at any time post-hematopoietic cell transplant (post-HCT): a) Dependent disease, defined as, when glucocorticoid (prednisolone doses greater than or equal to [>=] 0.25 milligram per kilogram per day (mg/kg/day)or >=0.5 milligram per kilogram (mg/kg) every other day) are needed to prevent recurrence or progression of manifestations as demonstrated by unsuccessful attempts to taper the dose to lower levels on at least 2 occasions, separated by at least 8 weeks. In case of inability to taper the dose to less than or equal to (<=)0.25 mg/kg/day or <=0.5 mg/kg every other day (prednisolone doses) due to recurrence or progression of cGVHD manifestations, it is considered as steroid-dependent disease if the lowest tapering dose of the second occasion is equal or higher than the lowest tapering dose of the first occasion; b) Refractory disease, defined as, when cGVHD manifestations progress despite the use of a regimen containing glucocorticoid (prednisolone at >=1 mg/kg/day for at least 1 week) or persist without improvement despite continued treatment with glucocorticoid (prednisolone at >=0.5 mg/kg/day or 1 mg/kg every other day) for at least 4 weeks
- Participants must be receiving baseline systemic glucocorticoid therapy for cGVHD at study entry. The dose of steroids must be stable for 14 days prior to starting ibrutinib
- At the time of trial enrollment, participants may be receiving other immunosuppressive therapies in addition to glucocorticoids. Immunosuppressant doses must be stable for 14 days prior to starting ibrutinib
- Clinically stable or worsening cGVHD for a minimum of 14 days between screening and Day 1 cGVHD response assessment
- Karnofsky or Lansky (participants less than [<]16 years) performance status >=60
Exclusion Criteria:
- Active acute graft versus host disease (GVHD)
- More than 3 previous systemic treatments for cGVHD. Treatment with glucocorticoids is considered a treatment for cGVHD and should be included in determining the number of previous treatments
- History of treatment with a tyrosine kinase inhibitor (example [e.g.] imatinib), purine analogs, or other cancer chemotherapy in the 4 weeks prior to starting ibrutinib. Participants may have received ibrutinib pre-transplant for other reasons besides cGVHD such as for the treatment of leukemia or lymphoma
- History of treatment with monoclonal T and B cell antibodies in the 8 weeks prior to starting ibrutinib
- Vaccinated with live, attenuated vaccines within 4 weeks of first dose of ibrutinib
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Ibrutinib
Participants will receive 420 milligram (mg) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
|
Participants will receive 420 mg (3 * 140 mg capsules) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR])
Tidsramme: Approximately up to 4.5 years
|
ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR).
Response is defined by the National Institutes of Health (NIH) Consensus Development Project Criteria (2014) and must occur, in the absence of new therapy for chronic graft versus host disease (cGVHD) and absence of progression of underlying disease or death.
CR: Resolution of all manifestations in each organ or site.
PR: Improvement in at least 1 organ or site without progression in any other organ or site.
cGVHD Progression: Clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.
|
Approximately up to 4.5 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants with Sustained Response
Tidsramme: Approximately up to 4.5 years
|
Percentage of participants with sustained response is defined as rate of NIH defined CR or PR that was sustained for at least 20 weeks.
|
Approximately up to 4.5 years
|
Duration of Response (DOR)
Tidsramme: From the date of initial documentation of a response to the date of first documented evidence of progressive cGVHD or death, whichever occurs first (approximately up to 4.5 years)
|
DOR is defined as the duration of time from the date of initial response (CR or PR) to the date of progressive cGVHD or death, whichever occurs first.
|
From the date of initial documentation of a response to the date of first documented evidence of progressive cGVHD or death, whichever occurs first (approximately up to 4.5 years)
|
Percentage of Participants with cGVHD response at Each Timepoint of Efficacy Evaluation
Tidsramme: Screening, Day 1 Weeks 1, 5, 13 and 25, Week 37 and every 12 weeks (q12w) thereafter, Progressive cGVHD Visit, End-of-Treatment and Response Follow-up Visits (until progressive cGVHD) q12w (approximately up to 4.5 years)
|
Percentage of Participants with cGVHD response at each timepoint of efficacy evaluation (cGVHD response rate) is defined as percentage of participants with NIH defined CR or PR at each timepoint.
|
Screening, Day 1 Weeks 1, 5, 13 and 25, Week 37 and every 12 weeks (q12w) thereafter, Progressive cGVHD Visit, End-of-Treatment and Response Follow-up Visits (until progressive cGVHD) q12w (approximately up to 4.5 years)
|
Change in the Amount of Corticosteroid Required Per Participant Over Time
Tidsramme: Screening, Day 1 Weeks 1, 2, 5, 9, 13, 17, 21, 25, Week 37 and q12w thereafter, Progressive cGVHD Visit, End-of-Treatment and Response Follow-up Visits (until progressive cGVHD) q12w (approximately up to 4.5 years)
|
Change in the amount of corticosteroid required per participant over time will be monitored across the study.
|
Screening, Day 1 Weeks 1, 2, 5, 9, 13, 17, 21, 25, Week 37 and q12w thereafter, Progressive cGVHD Visit, End-of-Treatment and Response Follow-up Visits (until progressive cGVHD) q12w (approximately up to 4.5 years)
|
Improvement in Symptom Burden Measured by the Lee cGVHD Symptom Scale
Tidsramme: Screening, Day 1 Weeks 1, 5, 13 and 25, Week 37 and q12w thereafter, Progressive cGVHD Visit, End-of-Treatment and Response Follow-up Visits (until progressive cGVHD) q12w (approximately up to 4.5 years)
|
Lee cGVHD Symptom Scale is a participant-reported symptom scale.
It includes a total of 30 items within the following 7 domains: Skin, eyes and mouth, breathing, eating and digestion, muscles and joints, energy, mental and emotional for evaluating overall response.
Response options range from 0 to 4 and includes: "not at all" (0), "Slightly" (1), "Moderately" (2), "Quite a bit" (3), and "extremely" (4), and yield an overall score.
A change greater than or equal to (>=) 7 points on the Lee cGVHD Symptom Scale will be considered significant and relates to improvement in quality of life (QoL).
|
Screening, Day 1 Weeks 1, 5, 13 and 25, Week 37 and q12w thereafter, Progressive cGVHD Visit, End-of-Treatment and Response Follow-up Visits (until progressive cGVHD) q12w (approximately up to 4.5 years)
|
Number of Participants with Adverse Events (AEs) as a Measure of Safety
Tidsramme: From signing Informed Consent Form until 30 days after the last dose of study treatment (approximately up to 4.5 years)
|
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE does not necessarily have a causal relationship with the intervention.
An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.
|
From signing Informed Consent Form until 30 days after the last dose of study treatment (approximately up to 4.5 years)
|
Number of Participants with Clinical Laboratory Abnormalities
Tidsramme: Screening, Day 1 Weeks 1, 2, 5, 9, 13, 17, 21, 25, Week 37 and q12w thereafter, Progressive cGVHD Visit, End-of-Treatment (approximately up to 4.5 years)
|
Number of participants with clinical laboratory abnormalities will be reported.
|
Screening, Day 1 Weeks 1, 2, 5, 9, 13, 17, 21, 25, Week 37 and q12w thereafter, Progressive cGVHD Visit, End-of-Treatment (approximately up to 4.5 years)
|
Area Under the Plasma Concentration-Time Curve from Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of Ibrutinib
Tidsramme: Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
AUC (0-last) is defined as the area under the plasma concentration-time curve from time zero to time of last measurable concentration.
|
Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Area Under the Plasma Concentration-Time Curve from Time Zero to 24 Hours (AUC [0-24]) of Ibrutinib
Tidsramme: Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
AUC (0-24) is defined as the area under the plasma concentration-time curve from time zero to 24 hours.
|
Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
Tidsramme: Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Cmax is defined as the maximum observed plasma concentration.
|
Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ibrutinib
Tidsramme: Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Tmax is defined as actual sampling time to reach maximum observed plasma concentration.
|
Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Elimination Half-Life (t1/2) of Ibrutinib
Tidsramme: Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration.
It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
|
Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
AUC (0-last) of Metabolite PCI-45227
Tidsramme: Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
AUC (0-last) is defined as the area under the plasma concentration-time curve from time zero to time of last measurable concentration.
|
Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
AUC (0-24) of Metabolite PCI-45227
Tidsramme: Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
AUC (0-24) is defined as the area under the plasma concentration-time curve from time zero to 24 hours.
|
Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Cmax of Metabolite PCI-45227
Tidsramme: Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Cmax is defined as the maximum observed plasma concentration.
|
Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Tmax of Metabolite PCI-45227
Tidsramme: Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Tmax is defined as actual sampling time to reach maximum observed plasma concentration.
|
Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
t1/2 of Metabolite PCI-45227
Tidsramme: Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration.
It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
|
Day 1 (Predose, 1 hour [h], 2h, 4h, 6h) Weeks 1 and 2; Day 2 (Predose) Week 1
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. mai 2018
Primær fullføring (Faktiske)
29. november 2021
Studiet fullført (Faktiske)
29. november 2021
Datoer for studieregistrering
Først innsendt
16. mars 2018
Først innsendt som oppfylte QC-kriteriene
16. mars 2018
Først lagt ut (Faktiske)
22. mars 2018
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
3. januar 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
30. desember 2021
Sist bekreftet
1. desember 2021
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CR108443
- 54179060GVH3001 (Annen identifikator: Janssen Pharmaceutical K.K., Japan)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Ja
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Graft vs vertssykdom
-
University of SalamancaHaematology Service,University Hospital of Salamanca, MªConsuelo del...UkjentGraft-vs-Host Disease (GVHD)Spania
-
Astellas Pharma IncFullførtBenmargstransplantasjon | Pode versus vertssykdom | Graft-versus-vertssykdom | Graft-Vs-Host-sykdomJapan
-
Astellas Pharma IncFullførtBenmargstransplantasjon | Pode versus vertssykdom | Graft-versus-vertssykdom | Graft-Vs-Host-sykdomJapan
-
Ladan EspandarTilbaketrukketGraft-versus-host-sykdomForente stater
-
Incyte CorporationFullførtGraft-versus-host-sykdom (GVHD)Belgia, Italia, Spania, Saudi-Arabia, Tyrkia, Storbritannia, Tyskland, Hellas, Canada, Østerrike, Frankrike, Israel, Nederland, Sverige, Sveits, Korea, Republikken, Bulgaria, Japan, Norge, Tsjekkia, Den russiske føderasjonen, Jordan, ... og mer
-
Incyte CorporationGodkjent for markedsføringGraft-versus-host-sykdom (GVHD)Forente stater
-
Karolinska InstitutetFullførtOverlevelse | Graft-versus-host-sykdomSverige
-
Sameem M. Abedin, MDRekrutteringGraft-versus-host-sykdomForente stater
-
Fundación para la Investigación del Hospital Clínico...Fullført
-
Sheba Medical CenterUkjent
Kliniske studier på Ibrutinib
-
Christian BuskeAmgen; Janssen, LPRekrutteringWaldenstrom makroglobulinemiØsterrike, Tyskland, Hellas
-
TG Therapeutics, Inc.FullførtMantelcellelymfom | Kronisk lymfatisk leukemiForente stater
-
Janssen Research & Development, LLCFullført
-
Johnson & Johnson Private LimitedFullførtLymfom, mantelcelle | Leukemi, lymfatisk, kronisk, B-celleIndia
-
Janssen Research & Development, LLCFullført
-
The Lymphoma Academic Research OrganisationJanssen Pharmaceutica N.V., BelgiumAvsluttet
-
Oncternal Therapeutics, IncUniversity of California, San Diego; Pharmacyclics LLC.; California Institute...Aktiv, ikke rekrutterendeMantelcellelymfom | Marginal sone lymfom | B-celle kronisk lymfatisk leukemi | Lite lymfatisk lymfomForente stater
-
Pharmacyclics Switzerland GmbHJanssen Biotech, Inc., including Johnson & JohnsonPåmelding etter invitasjonLymfom, B-celle | Lymfom, Non-Hodgkin | Solid svulst | Leukemi, B-celle | Graft vs vertssykdomForente stater, Spania, Taiwan, Storbritannia, Australia, Italia, Den russiske føderasjonen, Canada, New Zealand, Korea, Republikken, Frankrike, Tyrkia, Tsjekkia, Ungarn, Polen, Sverige
-
Janssen-Cilag Ltd.FullførtLymfom, mantelcelle | Leukemi, lymfatisk, kronisk, B-celleFrankrike
-
The Lymphoma Academic Research OrganisationFullførtIntraokulært lymfom | Primært sentralnervelymfomFrankrike